Last edition
News about "Hormone-Sensitive Prostate Cancer "
US FDA Expands Approval of Novartis' Pluvicto for Earlier Treatment of Advanced Prostate Cancer
The US FDA has approved Novartis' Pluvicto for use in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, expanding access to the radioligand therapy at an earlier stage of disease.
Hormone-Sensitive Prostate Cancer | 03/08/2026 | By News Bureau
FDA Grants Priority Review to Pfizer's Talzenna-Xtandi Combination Advanced Prostate Cancer
Pfizer’s Talzenna-Xtandi combination receives FDA Priority Review for HRR gene-altered metastatic castration-sensitive prostate cancer, with Phase 3 data demonstrating a 52 percent reduction in the risk of disease progression or death.
Hormone-Sensitive Prostate Cancer | 24/07/2026 | By News Bureau
Talzenna Plus Xtandi Improve Progression-Free Survival in Metastatic Prostate Cancer
Talzenna plus Xtandi significantly improved Progression-Free Survival (PFS) in the phase-III TALAPRO-3 trial, reducing the risk of disease progression or death in HRR-mutated Metastatic Prostate Cancer, with a positive trend in Overall Survival (OS).
Hormone-Sensitive Prostate Cancer | 21/03/2026 | By News Bureau | 129
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy